Tier 2 — strong

Oral quercetin supplementation and blood oxidative capacity in response to ultramarathon competition

John C Quindry, Steven R McAnulty, Mathew B Hudson, Peter Hosick, Charles Dumke, Lisa S McAnulty, Dru Henson, Jason D Morrow, David Nieman
International journal of sport nutrition and exercise metabolism 2008 18(6):601

Bibliography

PubMed
PMID 19164830
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignDouble-blind placebo-controlled ultramarathon trial
ModelHuman intervention research
Sample63 randomized runners; 39 finishers provided outcome samples
InterventionQuercetin 1,000 mg/day or control
Duration3 weeks before and during a 160-km race
EndpointsOxidative-stress measures; Exercise performance or recovery

What the study showed, in plain terms

Published in 2008, this source examined exercise and recovery. Design: Double-blind placebo-controlled ultramarathon trial. Sample/model: 63 randomized runners; 39 finishers provided outcome samples. The exposure or intervention was Quercetin 1,000 mg/day or control. Follow-up or treatment period: 3 weeks before and during a 160-km race.

Quercetin did not improve race performance or measured blood antioxidant capacity and oxidative damage.

Finisher-only analyses reduce the evaluable sample. This is part of the same Western States trial reported in other immune, cytokine, and exertion papers.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Exercise: Performance, Recovery and Muscle. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin did not improve race performance or measured blood antioxidant capacity and oxidative damage.
  • The recorded outcome domains were Oxidative-stress measures; Exercise performance or recovery.
  • The result applies to the tested exposure: Quercetin 1,000 mg/day or control; 3 weeks before and during a 160-km race.

What this study can and cannot tell us

  • Finisher-only analyses reduce the evaluable sample. This is part of the same Western States trial reported in other immune, cytokine, and exertion papers.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified